Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS

Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer

(2012) Samuel Murray et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center study

(2012) Paola Ulivi et al.   Journal of Translational Medicine

Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer

(2012) Alexandra Voutsina et al.   MODERN PATHOLOGY

Antitumor Activity of SNX-2112, a Synthetic Heat Shock Protein-90 Inhibitor, in MET-Amplified Tumor Cells with or without Resistance to Selective MET Inhibition

(2011) T. Bachleitner-Hofmann et al.   CLINICAL CANCER RESEARCH

Is There a Role for IGF1R and c-MET Pathways in Resistance to Cetuximab in Metastatic Colorectal Cancer?

(2011) Alessandro Inno et al.   Clinical Colorectal Cancer

Mutations in BRAF correlate with poor survival of colorectal cancers in Chinese population

(2011) Jyh-Ming Liou et al.   INTERNATIONAL JOURNAL OF COLORECTAL DISEASE

Early Clinical Development of ARQ 197, a Selective, Non-ATP-Competitive Inhibitor Targeting MET Tyrosine Kinase for the Treatment of Advanced Cancers

(2011) A. A. Adjei et al.   ONCOLOGIST

Detection of Hepatocyte Growth Factor (HGF) Ligand-c-MET Receptor Activation in Formalin-Fixed Paraffin Embedded Specimens by a Novel Proximity Assay

(2011) Rajiv Dua et al.   PLoS One

Impact of KRAS, BRAF, PIK3CA Mutations, PTEN, AREG, EREG Expression and Skin Rash in ≥2nd Line Cetuximab-Based Therapy of Colorectal Cancer Patients

(2011) Zacharenia Saridaki et al.   PLoS One

The role of the c-Met pathway in lung cancer and the potential for targeted therapy

(2011) Martin Sattler et al.   Therapeutic Advances in Medical Oncology

HGF Rescues Colorectal Cancer Cells from EGFR Inhibition via MET Activation

(2010) D. Liska et al.   CLINICAL CANCER RESEARCH

Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer

(2010) Alberto Bardelli et al.   JOURNAL OF CLINICAL ONCOLOGY

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

(2010) Wendy De Roock et al.   LANCET ONCOLOGY

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer

(2009) J Souglakos et al.   BRITISH JOURNAL OF CANCER

PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies

(2009) A. Sartore-Bianchi et al.   CANCER RESEARCH

KRASandBRAFMutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial

(2009) Susan D. Richman et al.   JOURNAL OF CLINICAL ONCOLOGY

PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer

(2009) Fotios Loupakis et al.   JOURNAL OF CLINICAL ONCOLOGY

WDR19 Expression is Increased in Prostate Cancer Compared with Normal Cells, but Low-Intensity Expression in Cancers is Associated with Shorter Time to Biochemical Failures and Local Recurrence

(2008) B. Lin et al.   CLINICAL CANCER RESEARCH

EGFR Antagonists in Cancer Treatment

(2008) Fortunato Ciardiello et al.   NEW ENGLAND JOURNAL OF MEDICINE

Signaling networks assembled by oncogenic EGFR and c-Met

(2008) A. Guo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA